Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 199,378 shares of the pharmaceutical company’s stock after purchasing an additional 5,712 shares during the quarter. Public Employees Retirement System of Ohio owned about 0.08% of Vertex Pharmaceuticals worth $30,313,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Teacher Retirement System of Texas increased its stake in Vertex Pharmaceuticals by 4.4% in the second quarter. Teacher Retirement System of Texas now owns 2,661 shares of the pharmaceutical company’s stock valued at $343,000 after acquiring an additional 113 shares during the last quarter. Dupont Capital Management Corp bought a new position in Vertex Pharmaceuticals in the second quarter valued at $186,000. Legal & General Group Plc increased its stake in Vertex Pharmaceuticals by 4.9% in the second quarter. Legal & General Group Plc now owns 1,140,963 shares of the pharmaceutical company’s stock valued at $147,036,000 after acquiring an additional 53,020 shares during the last quarter. Ballentine Partners LLC bought a new position in Vertex Pharmaceuticals in the second quarter valued at $295,000. Finally, Douglass Winthrop Advisors LLC bought a new position in Vertex Pharmaceuticals in the second quarter valued at $271,000. 93.33% of the stock is currently owned by hedge funds and other institutional investors.

In related news, EVP Stuart A. Arbuckle sold 221 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $147.29, for a total value of $32,551.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jeffrey M. Leiden sold 125,000 shares of the stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $141.35, for a total transaction of $17,668,750.00. Following the completion of the transaction, the chief executive officer now directly owns 237,407 shares of the company’s stock, valued at $33,557,479.45. The disclosure for this sale can be found here. Over the last three months, insiders sold 343,519 shares of company stock valued at $49,488,660. 1.80% of the stock is owned by insiders.

Several analysts have issued reports on VRTX shares. Vetr lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price target for the company. in a research report on Monday, September 4th. Royal Bank of Canada upped their price target on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 18th. Needham & Company LLC restated a “buy” rating and set a $195.00 price target on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, DA Davidson started coverage on shares of Vertex Pharmaceuticals in a research report on Friday, September 29th. They set a “buy” rating and a $200.00 price target for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-four have issued a buy rating to the stock. Vertex Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $173.22.

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) opened at $145.86 on Friday. Vertex Pharmaceuticals Incorporated has a 1-year low of $71.46 and a 1-year high of $167.85. The firm has a market cap of $36,620.33, a PE ratio of 241.33, a PEG ratio of 3.46 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company had revenue of $578.20 million during the quarter, compared to the consensus estimate of $522.07 million. During the same period in the prior year, the firm earned $0.16 earnings per share. Vertex Pharmaceuticals’s revenue was up 39.7% on a year-over-year basis. research analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 EPS for the current year.

WARNING: “Vertex Pharmaceuticals Incorporated (VRTX) Shares Bought by Public Employees Retirement System of Ohio” was reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.thelincolnianonline.com/2017/12/16/vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-public-employees-retirement-system-of-ohio.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply